عنوان
پدید آورنده
موضوع
رده
کتابخانه
محل استقرار
شماره کتابشناسی ملی
شماره
97940P
زبان اثر
زبان متن نوشتاري يا گفتاري و مانند آن
انگلیسی
عنوان و نام پديدآور
عنوان اصلي
Prognostic factors of patients with newly diagnosed acute Promyelocytic Leukemia treated with Arsenic Tridoxide-based frontline therapy
عنوان اصلي
تعیین فاکتورهای پروگنوستیک با توجه به یافته های فلوسیتومتری، سیتوژنتیک و مولکولی در بیماران مبتلا به لوسمی پرومیلوسیتیک حاد درمان شده با رژیم های حاوی آرسنیک تری اکسید
نام عام مواد
[Dissertation]
نام نخستين پديدآور
Amirhossein Mirhosseini
نام نخستين پديدآور
امیر حسین میر حسینی
وضعیت نشر و پخش و غیره
نام ناشر، پخش کننده و غيره
Tehran University of Medical Sciences, Medicine school
تاریخ نشرو بخش و غیره
1400
مشخصات ظاهری
نام خاص و کميت اثر
68p
یادداشتهای مربوط به پایان نامه ها
جزئيات پايان نامه و نوع درجه آن
Doctor of Philosophy (phd)
نظم درجات
Adult hematology and oncology
زمان اعطا مدرک
2022/03/13 - 1400/12/22
یادداشتهای مربوط به خلاصه یا چکیده
متن يادداشت
Subject: Prognostic factors of patients with newly diagnosed acute Promyelocytic Leukemia treated with Arsenic Tridoxide-based frontline therapyBackground: Conventional karyotyping on banded metaphases has shown that, in addition to the specific t(15;17), 30% to 35% of acute promyelocytic leukemia(APL) patients have additional cytogenetic abnormalities(ACA), most frequently trisomy 8.Material & Methods: In this retrospective cohort study the patients with de novo APL who referred to Sharati Hospital since 2001, were enrolled. The diagnosis of APL was genetically confirmed in all cases by demonstration of the PML/RARα hybrid gene and/or the chromosomal translocation t(15;17)(q22;q21). For all patients, initial symptoms (hemorrhagic or thrombotic event), CBC, renal function tests, FDP, D-Dimer, Fibrinogen level, flow cytometry, PML RARa and cytogenetic study were recorded. A total of 200 patients (97 female and 103 male) with newly diagnosed APL received single-agent arsenic trioxide and 220 patients (118 female and 102 male) with newly diagnosed APL received ATRA plus ATO with or without chemotherapy.Results: This study shows that roughly 30% of patients with APL have ACA besides the t(15;17) that trisomy 8 is by far the most frequent abnormality, accounting for about 30% of the additional abnormalities. In the context of state-of-the-art treatment with on ATO based therapy, the presence of ACA, associated with leukocytosis and CD34 positive at flow cytometry. No significant relationship was seen between the presence of ACAs and OS/DFS, Moreover, reduced OS and DFS were found in patients with abnl(17p). Our study showed that the expression rate of CD2 was 27.1%, FLT3 mutation 31%, CD34 expression 20.4% and early mortality 9.1%. The patients with CD2 & CD34 expression presented with higher initial WBC count, coagulopathy and showed increased early mortality. The early mortality, OS and DFS showed obvious differences compared with CD2 & CD34 negative patients. Nevertheless, no significant relationship between OS, DFS and expression of CD2 & CD34 marker in the group of patients who survived after 30 days were seen. The patients who presented the FLT3-ITD mutation revealed no significant difference in OS as compared to the patients without mutation. Moreover, significant relations were seen between the presence of FLT3 mutation and leukocytosis, coagulopathy, APL differentiation syndrome and early mortality. Our study revealed early mortality rate was 9.1% and had meaningful correlation with: Age (more than 50 years), leukocytosis, Coagulopathy, Expression of CD2 & CD34.Conclusion: The lack of independent prognostic value of additional chromosomal abnormalities, FLT3 mutation and CD2, CD34 expression in acute promyelocytic leukemia does not support the use of alternative therapeutic strategies when such abnormalities are found.
موضوع (اسم عام یاعبارت اسمی عام)
موضوع مستند نشده
acute promyelocytic leukemia
موضوع مستند نشده
additional cytogenetic abnormalities
موضوع مستند نشده
FLT3 mutation
موضوع مستند نشده
CD2
موضوع مستند نشده
CD34 expression
نام شخص به منزله سر شناسه - (مسئولیت معنوی درجه اول )
کد نقش
, Author
کد نقش
, Author
مستند نام اشخاص تاييد نشده
Mirhosseini, Amirhossein
مستند نام اشخاص تاييد نشده
میر حسینی، امیر حسینی
نام شخص - ( مسئولیت معنوی درجه دوم )
کد نقش
, Thesis advisor
کد نقش
, Thesis advisor
کد نقش
, Thesis advisor
کد نقش
, Thesis advisor
کد نقش
, Consulting advisor
کد نقش
, Consulting advisor
کد نقش
, Consulting advisor
کد نقش
, Consulting advisor
مستند نام اشخاص تاييد نشده
Mousavi, Asadollah
مستند نام اشخاص تاييد نشده
موسوی، اسداله
مستند نام اشخاص تاييد نشده
Yaghmaee, Marjan
مستند نام اشخاص تاييد نشده
یغمایی، مرجان
مستند نام اشخاص تاييد نشده
Kasaeian, Amir
مستند نام اشخاص تاييد نشده
کساییان، امیر
مستند نام اشخاص تاييد نشده
Chardevali, Bahram
مستند نام اشخاص تاييد نشده
چهاردولی، بهرام
شناسه افزوده (تنالگان)
عنصر شناسه اي
Tehran University of Medical Sciences, Medicine school
مبدا اصلی
کشور
ایران
تاريخ عمليات
20220724
شماره دستیابی
شماره بازیابی
13598T
وضعیت انتشار
فرمت انتشار
p
اطلاعات رکورد کتابشناسی
نوع ماده
TL
کد کاربرگه
276903
اطلاعات دسترسی رکورد
سطح دسترسي
a
تكميل شده
Y
